

CLAIMS

1. The use of tenatoprazole in the manufacture of a medicament for the treatment of atypical and oesophageal symptoms of gastroesophageal reflux, digestive bleeding and dyspepsia.

5 2. Use according to claim 1, wherein tenatoprazole is administered via the oral route.

3. Use according to claim 1, wherein tenatoprazole is administered via the parenteral route.

10 4. Use according to any of the preceding claims, wherein tenatoprazole is administered at a rate of 10 to 120 mg per day.

15 5. Use according to claim 4, wherein tenatoprazole is presented in a unit dosage form containing 20 to 40 mg of active substance, associated with one or several pharmaceutically acceptable excipients and substrates.

6. Use according to any of claims 1 to 5, wherein the medicament is intended for the treatment of Barrett's oesophagus.

20 7. Use according to any of claims 1 to 5, wherein the medicament is intended for the treatment of nocturnal reflux.

8. Use according to any of claims 1 to 5, wherein the medicament is intended for the treatment of pseudo-ulcer dyspepsia.

25 9. Use according to any of claims 1 to 5, wherein the medicament is intended for the treatment of asthma, asthma-like acute dyspnoea, pharyngitis, dysphonia, pseudo-angina, paroxysmal cough and nocturnal cough.

30 10 Use according to any of claims 1 to 5, wherein the medicament is presented as a salt of sodium, potassium, magnesium or calcium.